News
Valvoline (VVV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Valvoline (VVV) reports results for the quarter ended September 2025. While this widely-known consensus outlook is
New Jersey Resources (NJR) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
New Jersey Resources (NJR) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus
Lowe's (LOW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
The market expects Lowe's (LOW) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended October 2025. This widely-known consensus outlook
Copa Holdings (CPA) Reports Next Week: Wall Street Expects Earnings Growth
Copa Holdings (CPA) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook
Consumers Cautious in Holiday Season: ETFs to Win/Lose
The upcoming holiday season, which includes retail sales boosting events like Thanksgiving, Black Friday, Cyber Monday and Christmas, could act as a tailwind for the broader markets. The season
Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect?
Shares of Rezolute, Inc. (RZLT) have gained 19.2% over the past four weeks to close the last trading session at $10.04, but there could still be a solid upside left in the stock if short-term price
Wall Street Analysts Think Helios Technologies (HLIO) Could Surge 26.75%: Read This Before Placing a Bet
Helios Technologies (HLIO) closed the last trading session at $53.12, gaining 7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet
Rapport Therapeutics, Inc. (RAPP) closed the last trading session at $25.5, gaining 2.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets
How Much Upside is Left in Klaviyo, Inc. (KVYO)? Wall Street Analysts Think 47.51%
Shares of Klaviyo, Inc. (KVYO) have gained 20.7% over the past four weeks to close the last trading session at $29.49, but there could still be a solid upside left in the stock if short-term price
Wall Street Analysts See a 33.38% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
LifeStance Health Group (LFST) closed the last trading session at $6.47, gaining 27.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
Alto Ingredients (ALTO) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Alto Ingredients, Inc. (ALTO) could be a good stock pick from a technical perspective. ALTO recently experienced a "golden cross" event, which saw its
Does Calix (CALX) Have the Potential to Rally 26.31% as Wall Street Analysts Expect?
Calix (CALX) closed the last trading session at $62.94, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
BigBear.ai's Ask Sage Buyout: Can it Become a GenAI Powerhouse?
BigBear.ai Holdings, Inc. BBAI is taking a transformative leap with its planned $250 million acquisition of Ask Sage, a fast-growing generative AI platform purpose-built for defense and national
Here's Why Hologic (HOLX) is a Strong Momentum Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service
Here's Why Raymond James Financial, Inc. (RJF) is a Strong Momentum Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research
Here's Why CBRE Group (CBRE) is a Strong Momentum Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different
Why Applied Industrial Technologies (AIT) is a Top Momentum Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates
Loar Holdings Inc. (LOAR) Q3 Earnings and Revenues Beat Estimates
Loar Holdings Inc. (LOAR) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.15 per share a year ago. These